Documentation Centre

Flash required
April 30, 2010
What is the status of PPAR-alpha agonists as targets for type 2 diabetes and cardiovascular disease?
By Bart Staels, PhD Department of Atherosclerosis, Institut Pasteur de Lille, UMR545 Inserm, University of Lille 2, Lille, France [0:41 min.] [3MB]

  • See all Expert Opinions of Bart Staels, PhD Department of Atherosclerosis, Institut Pasteur de Lille, UMR545 Inserm, University of Lille 2, Lille, France

Download Video


Key Words
Diabetes, Documentation Centre